more_reports

The Latest Life Sciences Tools & Diagnostics Articles from Streetwise Reports

New Alzheimer's Drugs Are Changing Brain Scans. This Company Is Preparing for What Comes Next

  ()
Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW2:XFRA) is developing dedicated brain PET imaging clinics as new Alzheimer's treatments introduce follow-up scans and Medicare removes its once-per-lifetime restriction.

AI Cuts Cancer Drug Discovery Costs From US$7.6 Million to US$1 Million in Just Two Years

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V; RKVTF:OTC; 7JO0:FSE) reported potent ATR inhibitor results from its kt-5000AI program after synthesizing 122 compounds, advancing its AI-powered drug discovery program toward development candidate selection.

MindBio Therapeutics Advances Voice AI Kiosk for Intoxication Detection Toward Commercial Pilot

  ()
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:FSE) completes next-generation Edge AI kiosk manufacture, advancing software validation for first commercial pilot in workplace safety screening.

Virtual Care Platform Grows US Visits 56%, Eyes Record Quarter

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTCQB; 939:FSE) completed 53,348 patient visits in the third quarter as U.S. visits jumped 56%, and the company expects record quarterly revenue. Find out why one analyst sees the AI telehealth company gaining meaningful traction in the U.S.

AI Cancer Drug Developer Secures Exclusive Rights in Expanded Brain Tumor Research Agreement

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V; RKVTF:OTCPK; 7JO0:FSE) expanded its AI-powered drug discovery agreement, securing exclusive rights to a defined ATR inhibitor profile and additional optimization work at no extra cost.

The FDA Clarified Its Rules for Medical AI. This Stock Could Be on the Right Side of Them

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTCQB; 939:FSE) continues to evolve its physician-led healthcare platform as revised FDA guidance, new state healthcare AI laws, and rising U.S. patient volumes reshape the regulatory and commercial environment.

Solving a 10,000-Pound Problem: This Company Aims to Reinvent the Brain Scan

  ()
Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW2:XFRA) is preparing to open its first dedicated brain PET imaging clinic as new Alzheimer's treatments drive demand for earlier, specialized imaging.

Sernova and Seraxis Bet on BetaNova to Take Diabetes Cell Therapy Into the Clinic

  ()
Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) and Seraxis Holdings Inc. are moving toward a merger to form BetaNova Biotherapeutics, with a type 1 diabetes cell therapy trial planned for early 2027. Find out why one analyst says Sernova found the right partner.

Rocket Doctor AI Delivers 3625 U.S. Patient Visits in July and August

  ()
Rocket Doctor AI reports 3,625 completed U.S. patient visits in the first two months of Q3 2026. The update highlights ongoing U.S. expansion and telehealth momentum for retail investors.

US Patient Visits Reach 93% of Prior Quarter's Total in Two Months

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported 3,625 completed U.S. patient visits in July and August, alongside 1,555 clinical hours as its U.S. operations expanded.

Ashok Kumar Thinks Commercial Conversion Should Establish the Next Year of Growth for DarioHealth

Research Report
  ()
DarioHealth's paid enrollment and additional signed business will determine the outcome.

Chart Buy Signals After Co. Targeting U.S. Alzheimer's Market Reports Final Major Regulatory Milestone

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson reviews Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW0:FRA) following its achievement of a major regulatory milestone.

AI Cancer Drug Pipeline Advances as 72% of Budget Shifts to Drug Discovery

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) cut its Q2 net loss 41% year over year while advancing three AI-powered cancer drug programs and closing a CA$1.99 million non-brokered private placement after quarter-end.

Rakovina Therapeutics Shifts 72% of Budget to AI Cancer Programs

  ()
Rakovina Therapeutics allocated 72% of its budget to AI-powered drug discovery in the second quarter of 2026, up from 57% in Q2 2025. See the three AI-supported DDR programs and upcoming milestones for retail investors.

Digital Health Platform Sees US Patient Visits Surge 196% and Quarterly YoY Revenue Jumps 43%

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported Q2 revenue of US$734,028 as U.S. patient visits nearly tripled and its in-network coverage expanded to approximately 24 million lives.

Telehealth Platform Delivers 196% U.S. Visit Growth in Q2

  ()
Rocket Doctor AI reports 43% revenue growth and 196% U.S. patient visit increase in Q2 2026, backed by 24 million covered lives and an expanding payer network.

Rocket Doctor AI Signs Strategic Network Agreement to Expand California Reimbursement Access

  ()
New multi-channel partnership opens contracted entry points into workers' compensation, auto medical, and Medicare networks, further extending Rocket Doctor AI Inc.'s (AIDR:CSE; AIRDF:OTC; 939:FRA) U.S. partnering strategy.

Rocket Doctor AI Secures California Network Deal Reaching 60M Consumers

  ()
Rocket Doctor AI enters a major provider network agreement in California covering 60 million consumers across multiple lines including workers compensation and Medicare. Learn the key details and next steps for investors.

Clinical AI Use Surges as Revenue Climbs and Doctors Embrace New Tools

  ()
Doximity Inc. (DOCS:NYSE) reported 7% revenue growth as workflow active prescribers increased more than 30% year over year and AI Search queries climbed more than 25% quarter over quarter.

Doximity AI Tools Fuel Physician Engagement Growth Amid Healthcare Digital Shift

  ()
Doximity reports fiscal Q1 revenue of $156.6 million with strong workflow growth. See how its AI suite and 85% physician reach position the company in expanding digital health markets.

AI Cancer Drug Developer Advances Pipeline as Funding Expands

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) is advancing in vivo testing and AI-driven lead optimization across its cancer drug pipeline as it expands relationships with AI companies and pursues additional non-dilutive funding.

Cancer Detection Firm Nears FDA Breakthrough Blood-Test Review

  ()
GRAIL Inc. (GRAL:NASDAQ) announces that an FDA committee will meet in September to evaluate the Premarket Approval (PMA) application for the Galleri multi-cancer early detection (MCED) blood test. Read why one financial expert thinks it will gain approval.

GRAIL Galleri Test Heads to FDA Panel for Multi-Cancer Screening Review

  ()
GRAIL Inc. prepares for its Sept. 23 FDA advisory committee meeting on the Galleri MCED test PMA, backed by large clinical studies and growing commercial revenue in the expanding multi-cancer early detection market.

DarioHealth Reports Q2 Revenue, with 62% Gross Margin as AI Platform Expands

  ()
DarioHealth Corp. (DRIO:NASDAQ) reported US$5.2 million in Q2 revenue, a 62% gross margin and US$13.1 million in contracted and late-stage ARR.

Showing Results: 1 to 25 of 59 Next